You're getting there. You're seeing an OR is a two-sided coin, and starting to understand the dynamics of the "threshold". Progress. Now consider what Missling said about our "better" threshold. Also what he said about our "better" CDR response compared to Lecanemab. And other comparisons.
It helps to understand the numbers. And objectively look at the graphs.
Looking forward to the AD full results. Hopefully it supports a superior efficacy signal.
News 
Market Data 
Discover 
AI
